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CONCLUSIONS: Many ADES seen in ED patients are
preventable and contribute substantially to hospital costs.
At a time when much emphasis is put on the limitation of
health expenses, here is a domain where expense-cutting
could probably be done reasonably easily, while increas-
ing quality of care.
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SIDE EFFECTS IN RENAL TRANSPLANTATION
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Assessing the economic impact of medication side effects
is critical for the accurate determination of the cost-effec-
tiveness of pharmaceuticals. It is often necessary to em-
ploy modeling techniques that utilize incidence rates that
are based on the literature.
OBJECTIVE: To present a calculation of the cost of ste-
roid-induced side effects in renal transplantation as an
example of a literature-based model and to discuss the as-
sumptions, techniques, and difficulties inherent in the
methodology.
METHODS: We estimated the incidence of adverse
events associated with steroids using evidence-based liter-
ature analyses. This evidence was used to construct a
Markov cost model for each side effect. Side effects in-
cluded in the analysis were hypertension (and its compli-
cations), post-transplant diabetes mellitus (PTDM), pe-
ripheral bone fractures, osteonecrosis of the hip, and
cataracts.
RESULTS: The side effect incidences reported in the liter-
ature vary, in part due to different definitions and follow-
up periods. Furthermore, data from randomized con-
trolled trials can be handicapped by low statistical power
to detect side effects and patient crossover or dropouts.
Confounding and bias are concerns in case-control and
cohort studies, and can complicate the determination of
attributable risk from cohort studies. Utilizing the inci-
dence data from the literature, the total 10-year dis-
counted cost for a 50-patient cohort was $266,000.
CONCLUSIONS: Extracting side effect incidence data
from the literature is a challenging but essential step in
modeling side effect costs. The variability in reported re-
sults should be ascertained, and assumptions requiring
clinical expertise are often required. We have demon-
strated the methodology and estimated the financial cost
of adverse events associated with steroids in renal trans-
plantation.
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The use of recombinant human erythropoietin (rhEPO)
and intravenous (IV) iron was studied in a group of pre-
mature neonates.
OBJECTIVE: The study purpose was to conduct a cost-
benefit analysis of the use of rhEPO and IV iron to reduce
the need of erythrocyte transfusions (Ets) in premature
neonates.
METHODS: Neonates 24-30 weeks gestational age (GA)
were considered for admission into the study. Patients
were excluded if severe hemolytic or hepatic disease, or
renal failure were present. If caretakers did not consent to
rhEPO and IV iron therapy, the patients were followed as
controls. For patients who were given caretaker consent,
treatment included IV iron 1 mg/kg/day in hyperalimen-
tion or IV fluids and 400 U/kg/dose of IV rhEPO three
times per week for 4 weeks, initiated at days 1-5 of life.
There were 41 patients in the rhEPO group and 13 in the
control group recruited over 12 months.
RESULTS: The mean number of Ets performed in the
first 4 weeks of life were 2.8 ::'::: 2.5 for the control group
and 1.9 ::'::: 2.7 for the rhEPO group (p = 0.28). The direct
cost of providing rhEPO and IV iron to the 41 study pa-
tients was $8160.11 The direct cost of one Et in our insti-
tution is $235.05. No indirect costs (adverse effects) were
noted. The average reduction in Ets per patient was 0.9
and if extrapolated to 41 patients would have resulted in
cost savings (benefit) of $8673.34. The benefit to cost ra-
tio of this program was 1.1:1.
CONCLUSION: rhEPO and IV iron use was associated
with a reduction of Ets and proved cost beneficial in a
small group of premature neonates ~30 weeks GA.
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Apligraf'>' is a full thickness manufactured living skin
equivalent indicated for the treatment of venous leg ul-
cers (VLU).
OBJECTIVE: To undertake a model-based retrospective
cost-effectiveness analysis (CEA), from a societal and
health care perspective, of the outpatient treatment of
VLU with the 4-1ayer high-compression bandage system
with and without one application of Apligraf'?".
METHODS: Because no prospective head-to-head study
of this comparison had yet been undertaken, a computer-
based model was developed. The model represented the
clinical consequences of the two approaches (ulcers
healed, time to heal, ulcer recurrence, infections, compli-
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cations) and the costs associated with these consequences
over two analytic horizons, 3 months and 6 months. Data
for the 3-month model was estimated based on two pub-
lished studies and clinical experience by a panel of seven
physicians from across Canada. The panel used an inter-
active modified Delphi approach culminating in a facili-
tated group meeting. Data for the 6-month model was ex-
trapolated from the shorter model using several different
plausible assumptions.
RESULTS: Over 3 months the use of Apligraf'>' in-
creased costs by $304 and $316 from the societal and the
health care perspectives, respectively, provided clinical
benefits of 22 ulcer days averted (UDA), and a C/E ratio
of $14/UDA for each perspective. Over 6 months the C/E
ratio was below $5/UDA for the societal and health care
perspectives. Sensitivity analysis indicated that the model
was relatively robust. Subgroup analyses suggested that
Apligraf'>' is particularly cost-effective in patients with
long-standing ulcers.
CONCLUSION: The model suggests that Apligrafl'" is
cost-effective in treating VLU, particularly when longer
analytic horizons are considered. Confirmation of this
finding in a prospective study is encouraged.
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To facilitate the evaluation of a new pediatric asthma man-
agement program, HUFF and PUFFSM The Children's
Asthma Program, a set of children's outcomes surveys, in-
cluding measures of quality of life (QoL) and self-efficacy,
were prepared. Each instrument was pretested through in-
dividual cognitive interviews with asthmatic children rang-
ing in age from four to eight years old.
QUESTIONNAIRE 1: The QoL measure, the Childhood
Asthma Questionnaire-Form A, was developed in En-
gland by Davina French and colleagues. Although it was
designed to measure both global and asthma-specific
QoL in young children, the questionnaire needed to be
adapted for use in the U.S. The most interesting cognitive
findings pertain to children's ability to select appropriate
responses and relate to item content. For example, the
youngest children had difficulty distinguishing between
certain response categories, and some items were not op-
timally worded for older children.
QUESTIONNAIRE 2: The original version of the self-
efficacy measure was developed by Thomas Creer for use
with adults. Because this program is targeted for young
children, we initially modified the scale by reducing the
number of items and adding graphics to clarify the re-
sponse categories. Cognitive findings indicated that chil-
dren had difficulty answering items about situations that
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did not trigger their asthma. Therefore, the survey was
limited to triggers most commonly acknowledged by chil-
dren. Gate questions were also added to ensure that children
would only be asked to provide self-confidence evaluations
about their personal triggers. Additional modifications
were aimed at making the questions and response catego-
ries as concrete as possible.
PSYCHOMETRIC EVALUATION: Psychometric prop-
erties of these instruments will be evaluated during the pi-
lot program which is currently under way.
